Article
Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial.
EBioMedicine - 1 Jul 2017
Yakoot Mostafa, Abdo Alaa M, Abdel-Rehim Siham, Helmy Sherine
Abstract excerpt
BACKGROUND: The most recent European Association for the Study of the Liver (EASL) 2016 Guidelines on treatment of hepatitis C (HCV), allowed for shortening the course of treatment for some subsets of patients with sofosbuvir/ledipasvir and with grazoprevir/elbasvir based on cutoff baseline HCV RNA values. We hypothesized that it would be prudent to also consider an objectively assuring very rapid, on-treatment,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.